Addex Therapeutics Ltd
SIX:ADXN
Income Statement
Earnings Waterfall
Addex Therapeutics Ltd
Revenue
|
2.5m
CHF
|
Operating Expenses
|
-16.8m
CHF
|
Operating Income
|
-14.4m
CHF
|
Other Expenses
|
-1.1m
CHF
|
Net Income
|
-15.5m
CHF
|
Income Statement
Addex Therapeutics Ltd
Jun-2017 | Dec-2017 | Jun-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
+120%
|
6
+1 028%
|
7
+19%
|
3
-62%
|
3
+11%
|
4
+34%
|
4
+17%
|
5
+2%
|
4
-15%
|
5
+26%
|
5
+2%
|
6
+13%
|
3
-44%
|
4
+32%
|
3
-38%
|
2
-13%
|
1
-36%
|
2
+64%
|
3
+9%
|
2
-3%
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(2)
|
(4)
|
(5)
|
(8)
|
(14)
|
(17)
|
(23)
|
(23)
|
(26)
|
(16)
|
(22)
|
(21)
|
(21)
|
(19)
|
(26)
|
(31)
|
(32)
|
(22)
|
(29)
|
(19)
|
(17)
|
|
Selling, General & Administrative |
(1)
|
(1)
|
(1)
|
(3)
|
(5)
|
(5)
|
(7)
|
(7)
|
(8)
|
(6)
|
(8)
|
(8)
|
(8)
|
(6)
|
(9)
|
(10)
|
(10)
|
(7)
|
(10)
|
(8)
|
(7)
|
|
Research & Development |
(1)
|
(3)
|
(4)
|
(5)
|
(9)
|
(12)
|
(16)
|
(16)
|
(18)
|
(10)
|
(10)
|
(8)
|
(8)
|
(13)
|
(16)
|
(21)
|
(22)
|
(15)
|
(20)
|
(15)
|
(13)
|
|
Depreciation & Amortization |
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(5)
|
(5)
|
(5)
|
0
|
0
|
0
|
0
|
0
|
1
|
4
|
4
|
|
Operating Income |
(2)
N/A
|
(3)
-85%
|
1
N/A
|
(1)
N/A
|
(11)
-698%
|
(15)
-28%
|
(19)
-29%
|
(19)
+1%
|
(22)
-17%
|
(12)
+44%
|
(18)
-43%
|
(16)
+7%
|
(15)
+5%
|
(16)
0%
|
(21)
-38%
|
(28)
-32%
|
(30)
-6%
|
(21)
+32%
|
(27)
-32%
|
(17)
+38%
|
(14)
+14%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(3)
|
(4)
|
0
|
(3)
|
(2)
|
(1)
|
0
|
0
|
0
|
(1)
|
|
Pre-Tax Income |
(2)
N/A
|
(3)
-84%
|
1
N/A
|
(2)
N/A
|
(12)
-602%
|
(15)
-28%
|
(19)
-29%
|
(19)
+1%
|
(22)
-17%
|
(13)
+42%
|
(19)
-46%
|
(19)
+0%
|
(19)
-2%
|
(15)
+20%
|
(25)
-62%
|
(30)
-23%
|
(31)
-2%
|
(21)
+33%
|
(27)
-31%
|
(17)
+38%
|
(15)
+9%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(2)
|
(3)
|
1
|
(2)
|
(12)
|
(15)
|
(19)
|
(19)
|
(22)
|
(13)
|
(19)
|
(19)
|
(19)
|
(15)
|
(25)
|
(30)
|
(31)
|
(21)
|
(27)
|
(17)
|
(15)
|
|
Net Income (Common) |
(2)
N/A
|
(3)
-84%
|
1
N/A
|
(2)
N/A
|
(12)
-602%
|
(15)
-28%
|
(19)
-29%
|
(19)
+1%
|
(22)
-17%
|
(13)
+42%
|
(19)
-46%
|
(19)
+0%
|
(19)
-2%
|
(15)
+20%
|
(25)
-62%
|
(30)
-23%
|
(31)
-2%
|
(21)
+33%
|
(27)
-31%
|
(17)
+38%
|
(15)
+9%
|
|
EPS (Diluted) |
-0.14
N/A
|
-0.25
-79%
|
0.03
N/A
|
-0.07
N/A
|
-0.44
-529%
|
-0.56
-27%
|
-0.72
-29%
|
-0.71
+1%
|
-0.84
-18%
|
-0.48
+43%
|
-0.56
-17%
|
-0.55
+2%
|
-0.55
N/A
|
-0.45
+18%
|
-0.64
-42%
|
-0.8
-25%
|
-0.64
+20%
|
-0.46
+28%
|
-0.44
+4%
|
-0.23
+48%
|
-0.2
+13%
|